# Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

> **NCT01330355** · PHASE3 · TERMINATED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 33 (actual)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** Besivance
- **DRUG:** Gatifloxacin

## Key facts

- **NCT ID:** NCT01330355
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2013-01
- **Final completion:** 2013-10
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01330355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01330355, "Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01330355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*